Thursday Apr 17
Scripps scientists win $2M research grant
The National Institutes of Health provided the five-year grant to a team led by Douglas Kojetin , an associate professor.
Wed Apr 16, 2014
Islet Sciences Announces Positive 12-Week Phase 2 Clinical Results...
Islet Sciences, Inc. and BHV Pharma today announced positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics.
Scientists awarded $2 million to study improvements in anti-diabetic drug design
Scientists from the Florida campus of The Scripps Research Institute have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive ... (more)
Tue Apr 15, 2014
KLAS-TV Las Vegas
Plaintiff in drug trial tells jury her story
For the first time, in front of a jury, one of the local women suing a major drug company told her story of how she was diagnosed with cancer after taking a medication meant to treat diabetes.
FDA Approves New Type 2 Diabetes Drug
TUESDAY April 15, 2014, 2014 -- Millions of Americans with type 2 diabetes have a new treatment option with the U.S. Food and Drug Administration's approval Tuesday of a once-weekly injectable drug, Tanzeum.
Thu Apr 10, 2014
Big News Network.com
Takeda and Eli Lilly to appeal $9bn punitive damages ordered by court
Our eNewspaper network was founded in 2002 to provide stand-alone digital news sites tailored for the most searched-for locations for news.
Wed Apr 09, 2014
Lupin gets USFDA approval for diabetes management drug
Lupin said its US subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Pioglitazone tablets from the US Food and Drugs Administration to market generic version of Takeda Pharmaceuticals USA Inc's Actos tablets.
Tue Apr 08, 2014
Huge Punitive Damages Award in Actos Bellwether Trial
A jury in Louisiana has awarded more than $9 billion in the first federal bellwether trial over claims that taking Actos increases the risk of getting bladder cancer.
Japana s Takeda to appeal US$6b diabetes drug verdict
A US jury ordered Japan's Takeda Pharmaceuticals to pay US$6 billion in punitive damages over a diabetes drug, but the country's biggest drug-maker is challenging the move.
Japan drugmaker Takeda says will fight $6.0 bn US damages order
Japan's biggest drugs maker Takeda Pharmaceutical said Tuesday it would fight a huge $6.0 billion damages order imposed by a US jury following a trial over the safety of its Actos diabetes medicine.
Fitch: Lilly's Ratings Intact Following $9B Actos Jury Verdict
Fitch rates LLY 'A' and the Rating Outlook is Stable. The U.S. district court in Louisiana this week rendered a $6 billion judgment against Takeda and a $3 billion penalty against LLY stemming from allegations that their Actos diabetes medicine is linked to bladder cancer.
Japan's Topix declines for third day
Japan's Topix index fell for a third day, posting its biggest decline in three weeks, as the yen strengthened and health-care and Internet stocks tumbled.
The Washington Post
Asian Stocks Decline Second Day as Health-Care, Tech Shares Drop
Asian stocks fell for a second day, following the biggest three-day rout in U.S. shares in more than two months, as health-care to technology companies retreated in Japan.
Mon Apr 07, 2014
Actos Verdict: Jury Orders Takeda, Eli Lilly To Pay $9 Billion In Damages
A picture taken on June 9, 2011 outside a pharmacy of the northern city of Lille, shows a pack of Actos antidiabetic drugs .
Takeda Loses First Federal Trial Over Actos Diabetes Drug
Takeda Pharmaceutical Co. lost the first federal court trial in the U.S. over claims it hid the cancer risks of its Actos diabetes medicine to protect billions of dollars in sales.
Thu Apr 03, 2014
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
A series of drug safety warnings have recently been made by drug authorities relating to adverse effects of rosiglitazone and pioglitazone on cardiovascular diseases and bladder cancer.